CRISPR-U™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With CRISPR-U™, Ubigene has
successfully edited over 3000 genes on more than 200 types of cell lines.
Objective
To create a Mouse Myorg Knockout
model in cell line by CRISPR-U™-mediated genome engineering.
Target gene info
Official symbol
Myorg
Gene id
329828
Organism
Mus musculus
Gene type
protein-coding
Official full symbol
myogenesis regulating glycosidase (putative)
Also known as
Gm762, Kiaa1161, NET37
Genomic regions
Chromosome 4
Summary
Predicted to enable hydrolase activity, hydrolyzing O-glycosyl compounds. Acts upstream of or within positive regulation of insulin-like growth factor receptor signaling pathway; positive regulation of protein kinase B signaling; and skeletal muscle fiber development. Located in endoplasmic reticulum membrane and nuclear membrane. Is expressed in several structures, including alimentary system; brain; connective tissue; genitourinary system; and hemolymphoid system gland. Human ortholog(s) of this gene implicated in basal ganglia calcification. Orthologous to human MYORG (myogenesis regulating glycosidase (putative)).
Strategy Summary
This gene has 0 protein coding transcripts：
Frame-shift
Fragment A
Fragment B
gRNA Detail
Strategy
Project Comprehensive Difficulty Assessment
According to the Red Cotton database: the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown.
EZ-editor™ Gene Expression Level
EZ-editor™ Gene Copy Number
EZ-editor™ Gene Expression Level
Result
In all cell lines, there is
12.2% cells with expression level below cutoff,
77.3% cells with low expression level,
10.5% cells with medium expression level
of Myorg gene.
Cell line is not selected, unable to assess the accurate expression level, for reference only.
In all cell lines, there is
68.4% cells with low copy number,
27.6% cells with medium copy number,
4.0% cells with high copy number
of Myorg gene.
Cell line is not selected, unable to assess the accurate copy number, for reference only.
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive CRISPR-U™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on CRISPR-U™ technology, Ubigene has accumulated over 6000 successful gene-editing cases from more than 300 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 4500+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!
